trial · primary record
Nivolumab
Urothelial Cancer
| Phase | Phase 3 |
|---|---|
| Status | COMPLETED |
| Sponsor | Unknown |
| Enrolment | 1314 |
| Primary completion | 2026-10-20 |
| Primary endpoint | Overall Survival (OS) in Cisplatin-ineligible Randomized Participants for Primary Study |
| Registry ID | NCT03036098 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-02T15:42:50.886Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT03036098
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.